Definium Therapeutics, Inc. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses), averaging -25.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-1.44 | not reported | not reported | |
| Q1 FY26 | $-0.47 | $-0.71 | -51.1% | Miss | |
| Q4 FY25 | $-0.45 | $-0.45 | +0.0% | Beat | Q4 FY25 call |
Back to DFTX overview · DFTX holders · DFTX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.